The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects

Overview of attention for article published in Leukemia, July 2012

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (81st percentile)
Good Attention Score compared to outputs of the same age and source (69th percentile)

Mentioned by

twitter: 2 X users

patent: 3 patents

Readers on

mendeley: 112 Mendeley

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 17,700 followers.

Epoxyketone proteasome inhibitors carfilzomib/oprozomib have effects against #myeloma & protect bone from resorption (http://t.co/1aM6L2xH).

Epoxyketone proteasome inhibitors carfilzomib/oprozomib have effects against #myeloma & protect bone from resorption (http://t.co/1aM6L2xH).

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.

Login to access the Sentiment Analysis related to this output.